Journal article
Clinical characterization of Collagen XII-related disease caused by biallelic COL12A1 variants
Annals of clinical and translational neurology, Vol.12(3), pp.602-614
03/2025
DOI: 10.1002/acn3.52225
PMCID: PMC11920742
PMID: 39923201
Abstract
While there have been several reports of patients with dominantly acting COL12A1 variants, few cases of the more severe recessive Collagen XII-related disorders have previously been documented.OBJECTIVEWhile there have been several reports of patients with dominantly acting COL12A1 variants, few cases of the more severe recessive Collagen XII-related disorders have previously been documented.We present detailed clinical, immunocytochemical, and imaging data on eight additional patients from seven families with biallelic pathogenic variants in COL12A1.METHODSWe present detailed clinical, immunocytochemical, and imaging data on eight additional patients from seven families with biallelic pathogenic variants in COL12A1.All patients presented with a consistent constellation of congenital onset clinical features: hypotonia, dysmorphic features, most notably gingival hypertrophy, prominent distal joint hyperlaxity, with co-occurring contractures of large joints, and variable muscle involvement, evident both clinically and on muscle imaging. Five patients presented with a severe congenital phenotype manifesting with profound weakness, significantly delayed or minimal attainment of motor milestones, respiratory insufficiency, and feeding difficulties. Three patients presented with mild-to-moderate muscle weakness and delayed milestones but were able to achieve independent ambulation. Patients were found to have biallelic loss-of-function COL12A1 variants, except for one family (p.I1393Ffs*11/p.A1110D). Consistent with the variable clinical spectrum, in vitro immunocytochemistry analysis in fibroblasts ranged from complete absence of Collagen XII expression in a patient with severe disease, to a mild reduction in a patient with milder disease.RESULTSAll patients presented with a consistent constellation of congenital onset clinical features: hypotonia, dysmorphic features, most notably gingival hypertrophy, prominent distal joint hyperlaxity, with co-occurring contractures of large joints, and variable muscle involvement, evident both clinically and on muscle imaging. Five patients presented with a severe congenital phenotype manifesting with profound weakness, significantly delayed or minimal attainment of motor milestones, respiratory insufficiency, and feeding difficulties. Three patients presented with mild-to-moderate muscle weakness and delayed milestones but were able to achieve independent ambulation. Patients were found to have biallelic loss-of-function COL12A1 variants, except for one family (p.I1393Ffs*11/p.A1110D). Consistent with the variable clinical spectrum, in vitro immunocytochemistry analysis in fibroblasts ranged from complete absence of Collagen XII expression in a patient with severe disease, to a mild reduction in a patient with milder disease.Here we characterize the clinical presentation, muscle imaging, and dermal fibroblast immunostaining findings associated with biallelic variants in COL12A1, further establishing COL12A1 as a recessive myopathic Ehlers-Danlos syndrome (mEDS) gene, and expanding the clinical spectrum to include a milder EDS phenotype.INTERPRETATIONHere we characterize the clinical presentation, muscle imaging, and dermal fibroblast immunostaining findings associated with biallelic variants in COL12A1, further establishing COL12A1 as a recessive myopathic Ehlers-Danlos syndrome (mEDS) gene, and expanding the clinical spectrum to include a milder EDS phenotype.
Details
- Title: Subtitle
- Clinical characterization of Collagen XII-related disease caused by biallelic COL12A1 variants
- Creators
- Riley M McCarty - National Institute of Neurological Disorders and StrokeDimah Saade - University of IowaPinki Munot - Great Ormond Street HospitalChamindra G Laverty - University of California San DiegoHailey Pinz - Saint Louis UniversityYaqun Zou - National Institutes of HealthMeghan McAnally - National Institute of Neurological Disorders and StrokePomi Yun - National Institute of Neurological Disorders and StrokeCuixia Tian - University of CincinnatiYing Hu - National Institute of Neurological Disorders and StrokeLucy Feng - Great Ormond Street HospitalRahul Phadke - National Hospital for Neurology and NeurosurgerySophia Ceulemans - Rady Children's Hospital-San DiegoPilar Magoulas - Texas Children's HospitalAndrew J Skalsky - Rady Children's Hospital-San DiegoJennifer R Friedman - University of California San DiegoStephen R Braddock - Saint Louis UniversitySarah B Neuhaus - National Institutes of HealthDenise M Malicki - Rady Children's Hospital-San DiegoMatthew N Bainbridge - Children’s InstituteShareef Nahas - Children’s InstituteDavid P Dimmock - Children’s InstituteStephen F Kingsmore - Children’s InstituteTimothy E Lotze - Texas Children's HospitalA Reghan Foley - National Institute of Neurological Disorders and StrokeFrancesco Muntoni - Great Ormond Street HospitalVolker Straub - Newcastle UniversitySandra Donkervoort - National Institutes of HealthCarsten G Bönnemann - National Institute of Neurological Disorders and Stroke
- Resource Type
- Journal article
- Publication Details
- Annals of clinical and translational neurology, Vol.12(3), pp.602-614
- DOI
- 10.1002/acn3.52225
- PMID
- 39923201
- PMCID
- PMC11920742
- NLM abbreviation
- Ann Clin Transl Neurol
- ISSN
- 2328-9503
- eISSN
- 2328-9503
- Publisher
- Wiley
- Grant note
- NIH National Institute of Neurological Disorders and StrokeSanofi GenzymeUltragenyxLGMD2I Research FundSamantha J. Brazzo FoundationLGMD2D FoundationKurt+Peter FoundationMuscular Dystrophy UKCoalition to Cure Calpain 3NIHR Newcastle Biomedical Research Centre (BRC)
We would like to thank the patients and their families for participating in our research study. We would also like to thank Gilberto ("Mike") Averion, Christine Jones, Kia Brooks, and Christopher Mendoza for their help in the clinic. We also thank Dr. Manuel Koch for his expertise. The work in C.G. Boennemann's laboratory is supported by intramural funds from the NIH National Institute of Neurological Disorders and Stroke. MYO-SEQ was funded by Sanofi Genzyme, Ultragenyx, LGMD2I Research Fund, Samantha J. Brazzo Foundation, LGMD2D Foundation and Kurt+Peter Foundation, Muscular Dystrophy UK, and Coalition to Cure Calpain 3. V. Straub is supported by the NIHR Newcastle Biomedical Research Centre (BRC).
- Language
- English
- Electronic publication date
- 02/09/2025
- Date published
- 03/2025
- Academic Unit
- Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Neurology (Pediatrics)
- Record Identifier
- 9984786453002771
Metrics
43 Record Views